The Way to Break the Game in Accelerating the Access of Innovative Drugs from the Perspective of Urban Benefits

Since the launch of the drug review reform in 2015, a series of policies for accelerating the launch of new drugs, including priority review and approval, special approval, clinically urgently needed drugs, conditional approval, and breakthrough therapy identification, have been implemented in an orderly manner, which has significantly improved the current situation of domestic new drug supply

If compared with five or six years ago, domestic patients needed to obtain some new drugs on the market overseas through "tourism abroad" and "micro-business purchasing", the current accelerated listing of new drugs has been able to better meet the clinical needs of domestic patients, and patients even Faced with more choices of similar drugs

It can be said that the availability of domestic innovative drugs has been greatly improved from the perspective of supply

Payment dilemma

The "National Medical Insurance Negotiation" is undoubtedly the best way to improve the availability of medicines at this stage, making it affordable to many patients who could not afford new medicines

Although many innovative drugs that have entered the national medical insurance catalogue are aimed at unmet clinical needs, they are obviously more proactive in negotiating medical insurance for new drugs with the same target or with the same mechanism.

From the perspective of industry development, the reform of drug regulation activates the innovation system, and patient demand will not only stay in the "basic medical insurance", but also need more high-value new drugs.

How to not only meet the rising "consumption upgrade" demand of patients for high-end new drugs, but also take into account the payment pressure of medical insurance funds, and break the traditional "medical impossibility triangle" theory? This has been widely discussed and concerned by the entire society in recent years Topic

Break the game

In addition to the pharmaceutical industry, the whole society is paying attention to innovative payment methods

Take urban inclusive insurance as an example.

Overview of Huimin Insurance Products in Key Cities

It is not difficult to find out by combing through the "Benefit People's Insurance" of key cities that the types of special drugs included in the early insurance are relatively small, generally no more than 20, and the products included are mostly tumor-related drugs or treatments

For example, the "Beijing Pratt & Whitney Health Insurance" launched at the end of July this year made such an attempt, incorporating the small interfering nucleic acid (siRNA) lipid-lowering drug Inclisiran (Leqvio®)

Considerations

Medical Rubik’s Cube is concerned that Inclisiran is still in clinical trials in China and has not yet been formally approved by China’s regulatory agencies.

According to the "China Cardiovascular Health and Disease Report 2019", the number of patients with cardiovascular disease in China has reached 330 million, and an average of about 3.

Although statins have a significant effect in reducing LDL-C, Lipitor, which has contributed more than $160 billion in sales to Pfizer, was born

Professor Huo Yong from Peking University First Hospital once stated that the drug lasts for up to half a year.

LDL-C reduction in Inclisiran's key trial ORION9/10/11

Boao has become a window for "first trial, first trial" of unlisted new drugs.

Concluding remarks

As a complementary means of innovative payment, Huimin Insurance in various regions has improved the availability of drug payment to a certain extent
.
By 2030, China will fully build a medical security system with basic medical insurance as the main body, medical assistance as the foundation, supplementary medical insurance, commercial health insurance, charitable donations, and mutual medical assistance
.

Whether it is to extend the accessibility of listed drugs, or to allow more people to use unlisted new drugs in advance; whether it is the treatment of tumors and rare diseases, or innovative treatments in the field of chronic diseases such as cardiovascular and hypertension; Before the diversified payment system is fully completed, the "first trial" is inseparable from the cross-border cooperation and innovative exploration between pharmaceutical companies and all parties, and it will gradually become a way to accelerate the accessibility of new drugs in China
.